Mar 15, 2022 | Press Releases
– Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023 – $29.7 Million in Cash as of December 31, 2021 – CUPERTINO, Calif., March 15, 2022 — Reviva Pharmaceuticals Holdings,...
Feb 1, 2022 | Press Releases
– RECOVER is a Phase 3, randomized, double-blind study with registrational intent – – Reviva anticipates expanding the clinical development of brilaroxazine into other neuropsychiatric indications – CUPERTINO, Calif., Feb. 01, 2022 —...
Jan 10, 2022 | Press Releases
– Brilaroxazine is a novel serotonin and dopamine receptor modulator currently being developed for diseases with dysfunctional serotonin signaling including neuropsychiatric and pulmonary indications – – Initiation of both Phase 3 trials is expected...
Dec 20, 2021 | Press Releases
CUPERTINO, Calif., Dec. 20, 2021 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
Nov 15, 2021 | Press Releases
– Initiation of a pivotal Phase 3 trial evaluating the efficacy and safety of brilaroxazine for the treatment of schizophrenia expected by year-end – – Additional Phase 3 trial evaluating the long-term safety of brilaroxazine in adult patients with...
Sep 15, 2021 | Press Releases
CUPERTINO, Calif., Sept. 15, 2021 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
